126 related articles for article (PubMed ID: 10811470)
21. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.
Atencio IA; Grace M; Bordens R; Fritz M; Horowitz JA; Hutchins B; Indelicato S; Jacobs S; Kolz K; Maneval D; Musco ML; Shinoda J; Venook A; Wen S; Warren R
Cancer Gene Ther; 2006 Feb; 13(2):169-81. PubMed ID: 16082381
[TBL] [Abstract][Full Text] [Related]
22. [Detection of p53 gene change and serum antibody level in phase II clinical trial of ad p53 gene therapy].
Zhao M; Xiao SW; Yang JX; Zhang SW; Lü YY
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3495-8. PubMed ID: 16686067
[TBL] [Abstract][Full Text] [Related]
23. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Horowitz J
Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
[TBL] [Abstract][Full Text] [Related]
24. [Adenoviral p53 gene therapy for human lung cancer].
Fujiwara T; Tanaka N
Gan To Kagaku Ryoho; 2003 Apr; 30(4):460-7. PubMed ID: 12722675
[TBL] [Abstract][Full Text] [Related]
25. New horizons: gene therapy for cancer.
Baselga J
Anticancer Drugs; 1999 Nov; 10 Suppl 1():S39-42. PubMed ID: 10630368
[TBL] [Abstract][Full Text] [Related]
26. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers.
Clayman GL; Frank DK; Bruso PA; Goepfert H
Clin Cancer Res; 1999 Jul; 5(7):1715-22. PubMed ID: 10430074
[TBL] [Abstract][Full Text] [Related]
27. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer.
Fujiwara T; Tanaka N; Kanazawa S; Ohtani S; Saijo Y; Nukiwa T; Yoshimura K; Sato T; Eto Y; Chada S; Nakamura H; Kato H
J Clin Oncol; 2006 Apr; 24(11):1689-99. PubMed ID: 16505415
[TBL] [Abstract][Full Text] [Related]
28. [A phase I trial of adenoviral p53 gene therapy for non-small cell lung cancer].
Fujiwara T; Kataoka M; Kawamata O; Tanaka N
Nihon Geka Gakkai Zasshi; 1999 Nov; 100(11):749-55. PubMed ID: 10629843
[TBL] [Abstract][Full Text] [Related]
29. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
30. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma.
Sterman DH; Molnar-Kimber K; Iyengar T; Chang M; Lanuti M; Amin KM; Pierce BK; Kang E; Treat J; Recio A; Litzky L; Wilson JM; Kaiser LR; Albelda SM
Cancer Gene Ther; 2000 Dec; 7(12):1511-8. PubMed ID: 11228529
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus-mediated gene transfer in canine eyes: a preclinical study for gene therapy of human uveal melanoma.
Andrawiss M; Maron A; Beltran W; Opolon P; Connault E; Griscelli F; Yeh P; Perricaudet M; Devauchelle P
J Gene Med; 2001; 3(3):228-39. PubMed ID: 11437328
[TBL] [Abstract][Full Text] [Related]
32. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer.
Schuler M; Rochlitz C; Horowitz JA; Schlegel J; Perruchoud AP; Kommoss F; Bolliger CT; Kauczor HU; Dalquen P; Fritz MA; Swanson S; Herrmann R; Huber C
Hum Gene Ther; 1998 Sep; 9(14):2075-82. PubMed ID: 9759934
[TBL] [Abstract][Full Text] [Related]
33. Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells.
Horio Y; Hasegawa Y; Sekido Y; Takahashi M; Roth JA; Shimokata K
Cancer Gene Ther; 2000 Apr; 7(4):537-44. PubMed ID: 10811471
[TBL] [Abstract][Full Text] [Related]
34. [Gene therapy for lung cancer].
Kataoka M; Fujiwara T; Tanaka N
Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):244-9. PubMed ID: 11904988
[TBL] [Abstract][Full Text] [Related]
35. Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53.
Odin L; Favrot M; Poujol D; Michot JP; Moingeon P; Tartaglia J; Puisieux I
Cancer Gene Ther; 2001 Feb; 8(2):87-98. PubMed ID: 11263530
[TBL] [Abstract][Full Text] [Related]
36. An agent that increases tumor suppressor transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo.
Kataoka M; Schumacher G; Cristiano RJ; Atkinson EN; Roth JA; Mukhopadhyay T
Cancer Res; 1998 Nov; 58(21):4761-5. PubMed ID: 9809972
[TBL] [Abstract][Full Text] [Related]
37. Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells.
Geutskens SB; van der Eb MM; Plomp AC; Jonges LE; Cramer SJ; Ensink NG; Kuppen PJ; Hoeben RC
Gene Ther; 2000 Aug; 7(16):1410-6. PubMed ID: 10981668
[TBL] [Abstract][Full Text] [Related]
38. p53 adenoviral vector (Ad-CMV-p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model.
Shirakawa T; Gotoh A; Gardner TA; Kao C; Zhang ZJ; Matsubara S; Wada Y; Hinata N; Fujisawa M; Hanioka K; Matsuo M; Kamidono S
J Gene Med; 2000; 2(6):426-32. PubMed ID: 11199263
[TBL] [Abstract][Full Text] [Related]
39. An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors.
Kuzmin AI; Galenko O; Eisensmith RC
Mol Ther; 2001 Mar; 3(3):293-301. PubMed ID: 11273770
[TBL] [Abstract][Full Text] [Related]
40. Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer.
Nemunaitis J; Meyers T; Senzer N; Cunningham C; West H; Vallieres E; Anthony S; Vukelja S; Berman B; Tully H; Pappen B; Sarmiento S; Arzaga R; Duniho S; Engardt S; Meagher M; Cheever MA
Mol Ther; 2006 Jun; 13(6):1185-91. PubMed ID: 16581300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
